Eiger Mountains

Investor Overview

Corporate Profile

Eiger is a late stage biopharmaceutical company focused on the development and commercialization of a pipeline of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs and for which no approved therapies exist.

The company’s lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection.  The company is rapidly advancing peginterferon lambda, a first-in-class interferon, toward registration for the treatment of HDV.  Eiger has initiated a rolling NDA submission for lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies with plans to complete NDA submission and MAA submission in the first quarter of 2020.  For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic
- HDV Phase 3 D-LIVR Study Progressing; Impact to Timeline - Peginterferon Lambda Investigator-Sponsored Studies in COVID-19 Initiating PALO ALTO, Calif. , April 1, 2020 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR ), focused on the development and commercialization of targeted
Toggle Summary Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies
- Progeria MAA Submitted to EMA and Granted Accelerated Assessment PALO ALTO,  Calif., March 23, 2020 /PRNewswire/ --   Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced
Toggle Summary Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
- Progeria MAA Submission Completed and Accelerated Assessment Granted by EMA - Progeria NDA Submission Complete by End of March 2020 - Phase 3 HDV Global D-LIVR Study Enrolling and Dosing PALO ALTO, Calif. , March 13, 2020 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc.
Toggle Summary Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer
- Launch Preparation Underway for Lonafarnib in Progeria - Market Development Activities Advancing for HDV Program PALO ALTO, Calif. , Jan. 7, 2020 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a late-stage clinical biopharmaceutical company focused on the development and
Upcoming EventsMore >>
More events are coming soon.
What's New
There are currently no items available.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site.